- Home
- ALGS
as 04-23-2025 4:00pm EST
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
| Founded: | 2018 | Country: | United States |
| Employees: | 70 | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 27.9M | IPO Year: | 2020 |
| Target Price: | $70.00 | AVG Volume (30 days): | 184.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -20.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.76 - $46.80 | Next Earning Date: | 05-06-2025 |
| Revenue: | $3,945,000 | Revenue Growth: | -74.60% |
| Revenue Growth (this year): | 580.86% | Revenue Growth (next year): | -94.94% |
Latest Aligos Therapeutics Inc. News
ALGS Breaking Stock News: Dive into ALGS Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Aligos Therapeutics Presents Positive Data at APASL 2025
TipRanks
a month ago
Biotech Alert: Searches spiking for these stocks today
GlobeNewswire
a month ago
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
a month ago
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates
GlobeNewswire
a month ago
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
2 months ago
Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025
GlobeNewswire
2 months ago
Aligos Therapeutics Announces $105 Million Private Placement Financing
Simply Wall St.
3 months ago
Here's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash Wisely
Compare ALGS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALGS Aligos Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.